| Literature DB >> 33214279 |
Fan Zhang1, Miao Zhao2, Doug R Braun1, Spencer S Ericksen3, Jeff S Piotrowski4, Justin Nelson4, Jian Peng5, Gene E Ananiev3, Shaurya Chanana1, Kenneth Barns1, Jen Fossen2, Hiram Sanchez2, Marc G Chevrette6,7,8, Ilia A Guzei9, Changgui Zhao1, Le Guo1, Weiping Tang1, Cameron R Currie6,7, Scott R Rajski1, Anjon Audhya10, David R Andes11, Tim S Bugni12.
Abstract
New antifungal drugs are urgently needed to address the emergence and transcontinental spread of fungal infectious diseases, such as pandrug-resistant Candida auris. Leveraging the microbiomes of marine animals and cutting-edge metabolomics and genomic tools, we identified encouraging lead antifungal molecules with in vivo efficacy. The most promising lead, turbinmicin, displays potent in vitro and mouse-model efficacy toward multiple-drug-resistant fungal pathogens, exhibits a wide safety index, and functions through a fungal-specific mode of action, targeting Sec14 of the vesicular trafficking pathway. The efficacy, safety, and mode of action distinct from other antifungal drugs make turbinmicin a highly promising antifungal drug lead to help address devastating global fungal pathogens such as C. auris.Entities:
Mesh：
Substances：
Year: 2020 PMID： 33214279 PMCID： PMC7756952 DOI： 10.1126/science.abd6919
Source DB: PubMed Journal: Science ISSN： 0036-8075 Impact factor: 47.728